Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases

Arthritis Care and Research

Volumn 62, Issue 6, 2010, Pages 749-754

  Caporali, R ^a   Bobbio Pallavicini, F ^a   Atzeni, F ^b   Sakellariou, G ^a   Caprioli, M ^a   Montecucco, C ^a   Sarzi Puttini, P ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB; VIRUS DNA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE DURATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART FAILURE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; PSORIATIC ARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; CARRIER STATE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953102456     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20130     Document Type: Article

References (50)

1. Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376
2. Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67 Suppl 3:iii2-25.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34 Suppl 1:S1-3.
4. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al, and the Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007;39:397-408.
5. Raimondo G, Pollicino T, Cacciolla I, Squadrito G. Occult hepatitis B infection. J Hepatol 2007;46:160-170
6. Zingarelli S, Airo P, Frassi M, Bazzani C, Scarsi M, Puoti M. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008; 60:22-27
7. Strasser SL, McDonald GB. Hepatitis viruses and hematopioetic cell transplantation: a guide to patient and donor management. Blood 1999;93:1127-1136
8. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
9. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-989
10. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-1365
11. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12: 974-976
12. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005;50:163-166
13. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43:397-401.
14. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease [letter]. Inflamm Bowel Dis 2007;13:1453-1454
15. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation [letter]. Inflamm Bowel Dis 2007;13:508-509
16. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [letter]. Ann Rheum Dis 2003;62:686-687
17. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003; 30:1624-1625
18. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy [letter]. Ann Rheum Dis 2005;64:788-789
19. Wendling D, Di Martino V, Prati C, Toussirot E, Herbein G. Spondyloarthropathy and chronic B hepatitis: effect of anti- TNF therapy. Joint Bone Spine 2009;76:308-311
20. Sakellariou GT, Chatzigiannis I. Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007;26:950-952
21. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008;14:245-246
22. Robinson H, Walker-Bone K. Anti-TNF-α for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 2009;48:450-451
23. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sanchez F, Rodriguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-720
24. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HbsAg carriers following anti-tumor necrosis factor-α therapy. J Rheumatol 2009; 36:2416-2420
25. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35: 421-424
26. Anelli MG, Torres DD, Manno C, Scioscia C, Iannone F, Covelli M, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005;52:2519-2520
27. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-α blockade: case reports. Clin Rheumatol 2008;27:1069-1071
28. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31:107-109
29. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006;45:1294-1297
30. Carroll MB, Bond MI. Use of tumour necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008;38:208-217
31. Li S, Kaur P, Chan V, Berney S. Use of tumour necrosis factor-α (TNFα) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of eleven patients. Clin Rheumatol 2009;28:787-791
32. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infection and anti-tumour necrosis factor-α therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006;21: 1366-1371
33. Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B. Hepatol Int 2008;2:440-456
34. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
35. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361-368
36. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
37. Smolen JS, Breedveld FC, Eberl G, Jones I, Leeming M, Wylie GL, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
38. Garrett S, Jenkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in anky-losing spondylitis: the Bath Ankylosing Spondylitis Activity Index. J Rheumatol 1994;21:2286-2291
39. Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, Kim LH, et al. Association of TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003; 12:2541-2546
40. Biermer M, Puro R, Schneider RJ. Tumor necrosis factor α inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-κB. J Virol 2003; 77:4033-4042
41. Torre D, Zeroli C, Giola M, Ferrario G, Fiori GP, Bonetta G, et al. Serum levels of interleukin-1 α, interleukin-1 β, interleukin- 6, and tumor necrosis factor in patients with acute viral hepatitis. Clin Infect Dis 1994;18:194-198
42. Sheron N, Lau J, Daniels H, Goka J, Eddleston A, Alexander GJ, et al. Increased production of tumour necrosis factor α in chronic hepatitis B virus infection. J Hepatol 1991;12:241-245
43. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108:1453-1463
44. Spengler U, Zachoval R, Gallati H, Jung MC, Hoffmann R, Riethmuller G, et al. Serum levels and in situ expression of TNF-α and TNF-α binding proteins in inflammatory liver diseases. Cytokine 1996;8:864-872
45. Calabrese LH, Zein N, Vasilopoulos D. Safety of anti tumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis 2004;63:18-24.
46. Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, et al. Lack of tumor necrosis factor α induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003;77:2469-2476
47. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor α. Proc Natl Acad Sci U S A 1997;94:8744-8749
48. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the antitumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010;31:20-34.
49. Zingarelli S, Frassi N, Bazzani C, Scarsi M, Puoti M, Airo P. Use of tumor necrosis factor-α-blocking agents in hepatitis B virus-positive patients: reports of three cases and review of literature. J Rheumatol 2009;36:1188-1194
50. Esteve M, Loras C, Gonzalez-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab treated Crohn's disease patient [letter]. Inflamm Bowel Dis 2007;13:1450-1451